Appili Therapeutics Inc. (TSE:APL – Get Rating) – Analysts at Zacks Small Cap increased their FY2023 earnings per share (EPS) estimates for shares of Appili Therapeutics in a research note issued to investors on Tuesday, February 21st. Zacks Small Cap analyst D. Bautz now expects that the company will earn ($0.08) per share for the year, up from their previous forecast of ($0.09).
Get
Appili Therapeutics alerts:
Appili Therapeutics (TSE:APL – Get Rating) last posted its quarterly earnings results on Tuesday, February 14th. The company reported C($0.02) earnings per share for the quarter, hitting the consensus estimate of C($0.02). The business had revenue of C$0.01 million during the quarter.
Appili Therapeutics Price Performance
Read More
- Carvana Skidding On Revenue Decrease, Heavy Debt Burden
- What Are Consumer Staples Stocks?
- Is Rocky Brands Dividend A Good Fit For Your Portfolio?
- Beyond Meat Stock Is Not Beyond Hope
- Analysts Holding As Pfizer Waits On Two Phase 3 Studies
Receive News & Ratings for Appili Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Appili Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Appili治療公司(多倫多證券交易所股票代碼：APL-GET評級)-在2月21日星期二發佈給投資者的一份研究報告中，Zack Small Cap的分析師上調了他們對Appili治療公司股票2023財年每股收益(EPS)的預期。Zack Small Cap分析師D.Bautz現在預計，該公司今年的每股收益將為0.08美元，高於此前預測的0.09美元。
到達
阿普利治療公司警報：
Appili Treateutics(多倫多證券交易所股票代碼：APL-GET Rating)最近一次公佈季度收益是在2月14日星期二。該公司公佈本季度每股收益為0.02加元，超過了普遍預期的0.02加元。該業務本季度的收入為10萬加元。
阿普利治療公司性價比
閱讀更多內容
- Carvana收入減少，債務負擔沉重
- 什麼是消費者史泰博股票？
- Rocky Brands的股息適合你的投資組合嗎？
- 超越肉類庫存並不是沒有希望
- 分析師等待輝瑞進行兩項第三階段研究
獲得《阿普利治療日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Appili Treateutics和相關公司的最新新聞和分析師評級的每日簡要摘要。
